Rezultati pretrage - Indrani Sarkar

  • Prikaz rezultata 1 – 5 od 5
Detaljiziraj rezultate
  1. 1
    A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

    A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors od Colin D. Weekes, A. Craig Lockhart, Patricia LoRusso, Elaine Murray, Erica Park, Mike Tagen, Jatinder Singh, Indrani Sarkar, Lars Müeller, Hatem Dokainish, Geoffrey I. Shapiro, Howard A. Burris

    Izdano 2020
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  2. 2
    Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial

    Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial od A. Dimitrios Colevas, Rastislav Bahleda, Fadi Braiteh, Ani Sarkis Balmanoukian, Irene Braña, Nicole G. Chau, Indrani Sarkar, Luciana Molinero, William Grossman, Fairooz F. Kabbinavar, Marcella Fassò, Carol O’Hear, John D. Powderly

    Izdano 2018
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  3. 3
    Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab

    Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab od Omid Hamid, Luciana Molinero, Christopher R. Bolen, Jeffrey A. Sosman, Eva Muñoz‐Couselo, Harriet M. Kluger, David F. McDermott, John D. Powderly, Indrani Sarkar, Marcus Ballinger, Marcella Fassò, Carol O’Hear, Daniel S. Chen, Priti S. Hegde, F. Stephen Hodi

    Izdano 2019
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  4. 4
    Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

    Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer od Leisha A. Emens, Cristina Cruz, Joseph P. Eder, Fadi Braiteh, Cathie T. Chung, Sara M. Tolaney, Irene Kuter, Rita Nanda, Philippe A. Cassier, Jean‐Pierre Delord, Michael S. Gordon, Ehab A. ElGabry, Ching-Wei Chang, Indrani Sarkar, William Grossman, Carol O’Hear, Marcella Fassò, Luciana Molinero, Peter Schmid

    Izdano 2018
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  5. 5
    Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

    Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study od Daniel P. Petrylak, Yohann Loriot, David R. Shaffer, Fadi Braiteh, John D. Powderly, Lauren C. Harshman, Paul Conkling, Jean‐Pierre Delord, Michael S. Gordon, Joseph W. Kim, Indrani Sarkar, Kobe Yuen, Edward E. Kadel, Sanjeev Mariathasan, Carol O’Hear, Sujata Narayanan, Marcella Fassò, Susheela Carroll, Thomas Powles

    Izdano 2021
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:

Alati za pretragu: